药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
4-Methoxyamphetamine
Abemaciclib
Fostemsavir may decrease the excretion rate of Abemaciclib which could result in a higher serum level.
4-Methoxyamphetamine
Dacomitinib
Fostemsavir may decrease the excretion rate of Dacomitinib which could result in a higher serum level.
4-Methoxyamphetamine
Duvelisib
Fostemsavir may decrease the excretion rate of Duvelisib which could result in a higher serum level.
4-Methoxyamphetamine
Delafloxacin
Fostemsavir may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
4-Methoxyamphetamine
Ertugliflozin
Fostemsavir may decrease the excretion rate of Ertugliflozin which could result in a higher serum level.
4-Methoxyamphetamine
Terodiline
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Terodiline.
4-Methoxyamphetamine
Macimorelin
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Macimorelin.
4-Methoxyamphetamine
Deutetrabenazine
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Deutetrabenazine.
4-Methoxyamphetamine
Glasdegib
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Glasdegib.
4-Methoxyamphetamine
Ribociclib
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Ribociclib.
4-Methoxyamphetamine
Ivabradine
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Ivabradine.
4-Methoxyamphetamine
Lumefantrine
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Lumefantrine.
4-Methoxyamphetamine
Artemether
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Artemether.
4-Methoxyamphetamine
Asenapine
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Asenapine.
4-Methoxyamphetamine
Iloperidone
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Iloperidone.
4-Methoxyamphetamine
Tetrabenazine
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Tetrabenazine.
4-Methoxyamphetamine
Zuclopenthixol
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Zuclopenthixol.
4-Methoxyamphetamine
Ivosidenib
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Ivosidenib.
4-Methoxyamphetamine
Dexverapamil
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Dexverapamil.
4-Methoxyamphetamine
Penfluridol
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Penfluridol.